A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorEli Lilly and Company
About this trial
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).
Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The study will last approximately 48 weeks, including screening.
Eligibility criteria
Qualifiers
A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months
Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet
BSA involvement of ≥0.5% on the face
F-VASI ≥0.5 and T-VASI ≥3, and
Disqualifiers
Participants who have other types of vitiligo that are not considered active or stable vitiligo
Currently have active forms of other disorders of pigmentation
Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
Trial design
Treatments tested in this trial
- LY4005130
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov